This article lists the prognostic data of 38 common malignant tumors (including subtypes) in the early, middle and late stages. The data comes from the SEER database in the United States. It is based on the data of various cancer patients included from 2011 to 2017, and is calculated for 5 years. survival rate. The number of cancer patients included in the SEER database is currently the largest, and some types even reach hundreds of thousands. Therefore, the degree of credibility is very high, and it can be said to be the most authoritative prognostic data currently. The tumor classification used by the
SEER database is not based on the Veterans Association for Lung Cancer (VALG) or TNM staging, but the SEER staging, which is divided into Localized, Regional and Distant, which is basically equivalent to the early, intermediate and late stages of cancer that we usually talk about. The chances of surviving beyond 5 years generally decrease progressively the later the stage is staged.
SEER staging explanation:
Early stage (localized): The tumor is limited to the organ, without surrounding invasion and lymph node metastasis . Usually equivalent to stage I and part II of the TNM staging (not entirely consistent).
Mid-stage (Regional): The tumor has invaded surrounding organs or has lymph node metastasis. Usually equivalent to some stages II and III of the TNM staging (not entirely consistent).
Late stage (Distant): combined with distant metastasis, usually equivalent to stage IV in the TNM staging.
All types of prognostic data include four columns of data: overall (that is, all cancer patients), early-stage cancer, intermediate-stage cancer, and late-stage cancer prognostic data. The ranking order is based on the overall 5-year survival rate (if the overall 5-year survival rate is the same, sort according to the late data), as shown in the attached figure:
